Cyclooxygenase-2 Overexpression is Common in Serrated and Non-Serrated Colorectal Adenoma, but Uncommon in Hyperplastic Polyp and Sessile Serrated Polyp/Adenoma by Kawasaki, Takako et al.
 
Cyclooxygenase-2 Overexpression is Common in Serrated and
Non-Serrated Colorectal Adenoma, but Uncommon in Hyperplastic
Polyp and Sessile Serrated Polyp/Adenoma
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Kawasaki, Takako, Katsuhiko Nosho, Mutsuko Ohnishi, Yuko
Suemoto, Jonathan N Glickman, Andrew T Chan, Gregory J
Kirkner, Mari Mino-Kenudson, Charles S Fuchs, and Shuji Ogino.
2008. Cyclooxygenase-2 overexpression is common in serrated
and non-serrated colorectal adenoma, but uncommon in
hyperplastic polyp and sessile serrated polyp/adenoma. BMC
Cancer 8: 33.
Published Version doi://10.1186/1471-2407-8-33
Accessed February 19, 2015 7:45:33 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:5346653
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAABioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Cyclooxygenase-2 overexpression is common in serrated and 
non-serrated colorectal adenoma, but uncommon in hyperplastic 
polyp and sessile serrated polyp/adenoma
Takako Kawasaki†1, Katsuhiko Nosho†1, Mutsuko Ohnishi†1, 
Yuko Suemoto1, Jonathan N Glickman2, Andrew T Chan3,4, 
Gregory J Kirkner4, Mari Mino-Kenudson5, Charles S Fuchs1,4 and 
Shuji Ogino*1,2,6
Address: 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA, 2Department of Pathology, Brigham and Women's 
Hospital, and Harvard Medical School, Boston, MA, USA, 3Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA, USA, 4Channing 
Laboratory, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA, 5Department of Pathology, 
Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA and 6Department of Epidemiology, Harvard School of Public 
Health, Boston, MA, USA
Email: Takako Kawasaki - takako_kawasaki@dfci.harvard.edu; Katsuhiko Nosho - katsuhiko_nosho@dfci.harvard.edu; 
Mutsuko Ohnishi - mutsuko_ohnishi@dfci.harvard.edu; Yuko Suemoto - yuyupon26@yahoo.co.jp; 
Jonathan N Glickman - jglickman@partners.org; Andrew T Chan - achan@partners.org; 
Gregory J Kirkner - gregory.kirkner@channing.harvard.edu; Mari Mino-Kenudson - mmino@partners.org; 
Charles S Fuchs - chales_fuchs@dfci.harvard.edu; Shuji Ogino* - shuji_ogino@dfci.harvard.edu
* Corresponding author    †Equal contributors
Abstract
Background:  Cyclooxygenase-2 (COX-2, PTGS2) plays an important role in colorectal
carcinogenesis. COX-2 overexpression in colorectal cancer is inversely associated with
microsatellite instability (MSI) and the CpG island methylator phenotype (CIMP). Evidence suggests
that MSI/CIMP+ colorectal cancer may arise through the serrated tumorigenic pathway through
various forms of serrated neoplasias. Therefore, we hypothesized that COX-2 may play a less
important role in the serrated pathway.
Methods: By immunohistochemistry, we assessed COX-2 expression in 24 hyperplastic polyps, 7
sessile serrated polyp/adenomas (SSA), 5 mixed polyps with SSA and adenoma, 27 traditional
serrated adenomas, 515 non-serrated adenomas (tubular adenoma, tubulovillous adenoma and
villous adenoma), 33 adenomas with intramucosal carcinomas, 96 adenocarcinomas with serration
(corkscrew gland) and 111 adenocarcinomas without serration.
Results: Strong (2+) COX-2 overexpression was more common in non-serrated adenomas (28%
= 143/515) than in hyperplastic polyps (4.2% = 1/24, p = 0.008) and serrated polyps (7 SSAs and 5
mixed polyps) (0% = 0/12, p = 0.04). Furthermore, any (1+/2+) COX-2 overexpression was more
frequent in non-serrated adenomas (60% = 307/515) than in hyperplastic polyps (13% = 3/24, p <
0.0001) and serrated polyps (SSAs and mixed polyps) (25% = 3/12, p = 0.03). Traditional serrated
adenomas and non-serrated adenomas showed similar frequencies of COX-2 overexpression.
Regardless of serration, COX-2 overexpression was frequent (~85%) in colorectal
Published: 29 January 2008
BMC Cancer 2008, 8:33 doi:10.1186/1471-2407-8-33
Received: 3 July 2007
Accepted: 29 January 2008
This article is available from: http://www.biomedcentral.com/1471-2407/8/33
© 2008 Kawasaki et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2008, 8:33 http://www.biomedcentral.com/1471-2407/8/33
Page 2 of 8
(page number not for citation purposes)
adenocarcinomas. Tumor location was not significantly correlated with COX-2 overexpression,
although there was a trend towards higher frequencies of COX-2 overexpression in distal tumors
(than proximal tumors) among hyperplastic polyps, SSAs, mixed polyps, traditional serrated
adenomas and adenocarcinomas.
Conclusion: COX-2 overexpression is infrequent in hyperplastic polyp, SSA and mixed polyp with
SSA and adenoma, compared to non-serrated and serrated adenoma. COX-2 overexpression
becomes more frequent as tumors progress to higher grade neoplasias. Our observations suggest
that COX-2 may play a less significant role in the serrated pathway of tumorigenesis; however,
COX-2 may still play a role in later stage of the serrated pathway.
Background
Cyclooxygenase-2 (COX-2 or PTGS2, the HUGO-
approved official gene symbol) has been considered to
have an important role in the development of various can-
cers, including colorectal cancer [1-4]. COX-2 overexpres-
sion is observed in approximately 70–80% of colorectal
cancer [5-7], and has been associated with poor prognosis
in some but not all studies [5,6]. Regular use of COX
inhibitor aspirin has been shown to decrease risks of
colorectal cancer [8] and adenoma [9], and epidemiologic
evidence supports that aspirin prevents colorectal cancer
by inhibiting COX-2 [10]. In addition, COX-2 selective
inhibitor celecoxib inhibits the growth of colorectal can-
cer cells in vitro [11,12]. Randomized trials have demon-
strated that celecoxib decrease a risk of recurrent
adenomas in high-risk individuals [13-15]. Thus, COX-2
is a promising chemopreventive target against colorectal
neoplasia [1,16,17]. In light of these observations, it may
be important to examine COX-2 expression levels in pre-
cursor lesions to predict effectiveness of chemoprevention
by COX-2 inhibition [10,18].
Serrated colorectal neoplasias comprise a family of lesions
bearing some histological similarities, including an over-
all serrated configuration of neoplastic epithelial cells
[19,20]. Serrated colorectal neoplasias include hyperplas-
tic polyps, sessile serrated polyps/adenomas (SSAs), pol-
yps with mixed features of SSA and adenoma, and
traditional serrated adenomas. Accumulating evidence
suggest that SSAs and polyps with mixed features of SSA
and adenoma be precursor lesions for colorectal cancers,
in particular, with BRAF mutation, high degree of MSI and
widespread promoter methylation referred to as the CpG
island methylator phenotype (CIMP) [19-23]. Thus, the
term ''the serrated pathway'' has been used for multistep
colorectal carcinogenesis through serrated precursor
lesions [22-24].
COX-2 overexpression in colorectal cancer is inversely
associated with MSI [25-27] and CIMP [27,28]. COX-2
has been shown to be frequently overexpressed in serrated
adenomas [29,30], but infrequently in hyperplastic pol-
yps [2,29-31]. COX-2 overexpression has been demon-
strated in polyps in hereditary mixed polyposis syndrome
[32] and familial juvenile polyposis [33], but not in
fibroblastic polyps [34]. However, to our knowledge, no
study has comprehensively examined COX-2 expression
levels in various serrated and non-serrated colorectal neo-
plasias. Therefore, in this study, we have evaluated COX-2
expressions in various serrated and non-serrated colorec-
tal neoplasias, including hyperplastic polyps, SSAs, tradi-
tional serrated adenomas, and adenocarcinomas with or
without serration.
Methods
Study group
In order to recruit patients into this study, we utilized the
databases of two large prospective cohort studies: the
Nurses' Health Study (N = 121,700 women) [35], and the
Health Professional Follow-up Study (N = 51,500 men)
[36]. Informed consent was obtained from all participants
prior to inclusion in the cohorts. A subset of the cohort
participants developed colorectal polyps or colorectal
cancers during prospective follow-up. Previous studies
confirmed that our colorectal polyps/adenomas and
colorectal cancers were representative as population-
based samples [8,10,35-37]. We requested paraffin
embedded tissue samples of colorectal polyps that were
endoscopically 1 cm or greater. Polyps endoscopically
measuring less than 1 cm did not give reliable results for
COX-2 expression because those small polyps became
even much smaller after formalin fixation and careful his-
topathologic examination for diagnosis at multiple levels
of sections (i.e., typically only approximately 1 mm of tis-
sue was left). Tumors were selected based on availability
of tumor tissue samples and assay results at the time of
this study. As a result, a total of 611 colorectal polyp cases
(290 from the men's cohort and 321 from the women's
cohort) were included in this study (mean age 60.8 years
old, median 62, standard deviation 8.2). For the purpose
of comparison, 207 colorectal adenocarcinomas from the
two cohorts were also evaluated for glandular serration
and COX-2 expression. Tissue collection and analyses
were approved by the Dana-Farber/Harvard Cancer
Center and Brigham and Women's Hospital Institutional
Review Boards.BMC Cancer 2008, 8:33 http://www.biomedcentral.com/1471-2407/8/33
Page 3 of 8
(page number not for citation purposes)
Histopathologic evaluations
Hematoxylin and eosin (HE) stained slides of the tumors
were reviewed by a pathologist (S.O.), and colorectal neo-
plasias were classified according to the previously
described criteria [19,38]: hyperplastic polyp, sessile ser-
rated polyp/adenoma (SSA), polyp with mixed features of
SSA and non-serrated adenoma (herein referred to as
"mixed polyp"), traditional serrated adenoma (Figure 1),
non-serrated adenomas (tubular adenoma, tubulovillous
adenoma, and villous adenoma), and adenoma with focal
intramucosal adenocarcinoma. All serrated polyps and
adenomas were reviewed by a second pathologist (M.M.)
and discrepant diagnoses were resolved by discussion. By
definition, tubular adenoma contains villous architecture
in <25% of adenomatous epithelium. Tubulovillous ade-
noma and villous adenoma have between 25% and 75%,
and greater than 75% of villous epithelium, respectively.
Serration in colorectal adenocarcinoma was evaluated
according to the previously published criteria [39,40].
Similar to hyperplastic polyps, serrated colorectal polyps
and traditional serrated adenomas, serrated adenocarci-
nomas were characterized by the presence of serrated epi-
thelial cells projecting into the lumen of neoplastic glands
(Figure 1). Glandular serration in colorectal cancer was
evaluated by a pathologist (J.N.G.).
Immunohistochemistry for COX-2
Methods for COX-2 immunohistochemistry were previ-
ously described [7,10]. Briefly, antigen retrieval was per-
formed by incubating deparaffinized tissue sections in
citrate buffer (BioGenex, San Ramon, CA, USA) by a
microwave for 15 min. Tissue sections were incubated
with 3% H2O2 (20 min), then with Avidin Block (Vector
Laboratories, Burlingame, CA, USA) (15 min), and then
with Biotin Block (Vector Laboratories) (15 min). Primary
anti-COX-2 antibody (Cayman Chemical, Ann Arbor, MI,
USA) (dilution 1:300) was applied overnight at 4°C.
Then, tissue sections were incubated with secondary anti-
mouse antibody (Vector Laboratories) (20 min), and then
with avidin-biotin complex conjugate (Vector Laborato-
ries). Tissue sections were visualized by diamino benzi-
dine (5 min) and methyl-green counterstain. Tissue
microarrays (TMAs) were constructed as previously
described [27], and used for immunohistochemistry in
only colorectal cancer cases. For cases in which results
from TMAs were equivocal, we stained whole tissue sec-
tions to obtain more definitive results. COX-2 expression
in adenoma/polyp cells was interpreted as negative (no
overexpression), weak overexpression (1+), or strong
overexpression (2+) (Figure 2). COX-2 expression in ade-
nomas and polyps was often heterogeneous and we inter-
preted as overexpression even if staining of tumor cells
was focal. Inflammatory cells served as an internal posi-
tive control. Appropriate positive control (colorectal can-
cer with known COX-2 overexpression) and negative
control (colorectal cancer with known COX-2 overexpres-
sion treated by water instead of anti-COX-2 antibody)
Immunohistochemistry for COX-2 in colorectal neoplasias Figure 2
Immunohistochemistry for COX-2 in colorectal neoplasias. 
A. No overexpression in colorectal adenoma (arrow). 
Inflammatory cells serve as an internal positive control 
(empty arrow). B. Weak (1+) overexpression in colorectal 
adenoma (arrows). C. Strong (2+) overexpression in color-
ectal adenoma (arrows). Note a junction between adenoma 
and normal appearing colon (empty block arrow). D. Strong 
(2+) overexpression in colorectal adenocarcinoma (arrows).
A  B 
C  D
Histopathology of serrated colorectal neoplasias Figure 1
Histopathology of serrated colorectal neoplasias. A. Sessile 
serrated polyp/adenoma (SSA) with abnormal crypt architec-
ture (flat-based crypt) (arrow). B. Mixed polyp with SSA 
(empty arrowhead) and non-serrated adenoma (empty 
arrow). C. traditional serrated adenoma with abundant eosi-
nophilic cytoplasm of epithelial cells. D. Colorectal adenocar-
cinoma with serration (arrows).
A  B
C  DBMC Cancer 2008, 8:33 http://www.biomedcentral.com/1471-2407/8/33
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were included in each run of immunohistochemistry.
COX-2 expression in colorectal cancer was interpreted as
previously described [10]. All immunohistochemically
stained slides were reviewed by a pathologist (S.O.)
blinded from clinical or other laboratory data. A subset of
cancer cases (N = 108) was reviewed for COX-2 expression
independently by two pathologists and the concordance
rate was 92% (kappa coefficient = 0.62, p < 0.001) [10].
Statistical analysis
Chi-square test (or Fisher's exact test when the number of
cases in any category was less than 10) was performed for
categorical data, and kappa coefficient to evaluate con-
cordance of interpretation of COX-2 by the two observers
was computed, using the SAS program (version 9.1, SAS
Institute, Cary, NC). All p values were two-sided, and sta-
tistical significance was set as p ≤ 0.05.
Results
COX-2 overexpression is infrequent in hyperplastic polyp, 
sessile serrated polyp/adenoma (SSA) and mixed polyp 
with SSA and non-serrated adenoma
There were totals of 605 colorectal polyps and adenomas,
including 24 hyperplastic polyps (HPs), 7 sessile serrated
polyp/adenomas (SSAs), 5 mixed polyps (MPs) with SSA
and non-serrated adenoma, 27 traditional serrated adeno-
mas (SAs), 393 tubular adenomas, 109 tubulovillous ade-
nomas, 13 villous adenomas, and 33 (non-serrated)
adenomas with intramucosal adenocarcinoma. For the
purpose of comparison, we also evaluated 207 colorectal
adenocarcinomas; 96 with at least focal serration and 111
without serration. Among all 605 colorectal polyps and
adenomas, weak (1+) COX-2 overexpression was
observed in 191 cases (32%), and strong (2+) COX-2
overexpression was observed in 160 cases (26%). There
was no significant difference in the frequencies of COX-2
overexpression between tubular adenomas, tubulovillous
adenomas and villous adenomas (Table 1). Therefore, we
combined these adenomas into "non-serrated adeno-
mas".
Compared to non-serrated adenomas, COX-2 expression
levels were generally lower in hyperplastic polyps, sessile
serrated adenomas (SSAs), and mixed polyps with SSA
and adenoma. In contrast to non-serrated adenomas
[showing 2+ COX-2 in 28% (143/515) of cases], strong
(2+) COX-2 expression was observed in none (0%) of 12
serrated lesions including 7 SSAs and 5 mixed polyps (p =
0.04) and in only 4.2% (1/24) of hyperplastic polyps (p =
0.008) (Table 1, Figure 3). Any (1+, 2+) COX-2 expression
was more common in non-serrated adenomas (60% =
307/515) than in hyperplastic polyps (13% = 3/24, p <
0.0001), and serrated lesions including SSAs and mixed
polyps (25% = 3/12, p = 0.03) (Table 1, Figure 4). Despite
the presence of serrated appearance, traditional serrated
adenomas showed the frequency of COX-2 overexpres-
sion similar to non-serrated adenomas. We noted that
most hyperplastic polyps were small (typically <3 mm on
glass slides) although these were supposed to be endo-
scopically ≥ 1 cm. Since we interpreted focal staining as
positivity, the proportion of negative hyperplastic polyps
might be merely function of size. Nonetheless, focal COX-
2 positivity was considered to be important, because focal
positive cells might progress to COX-2 positive advanced
lesions.
COX-2 overexpression was not correlated with serration in 
colorectal adenocarcinoma
In adenocarcinomas, regardless of the presence or absence
of serration, COX-2 overexpression was frequent (Table
1). Strong (2+) COX-2 overexpression was more common
in adenocarcinomas (65% = 135/207) than in non-ser-
rated adenomas (28% = 143/515, p < 0.0001) (Figure 3).
Any (1+ or 2+) COX-2 overexpression was also more com-
Table 1: Frequency of COX-2 overexpression in colorectal tumors
Tumor type Total COX-2 negative COX-2 weak (1+) 
overexpression
COX-2 strong (2+) 
overexpression
COX-2 any (1+, 2+) 
overexpression
Hyperplastic polyp (HP) 24 21 (88%) 2 (8.3%) 1 (4.2%) 3 (13%)
Sessile serrated polyp/adenoma (SSA) 7 5 (71%) 2 (29%) 0 2 (29%)
Mixed polyp with SSA and adenoma (MP) 5 4 (80%) 1 (20%) 0 1 (20%)
Total HP, SSA and MP 36 30 (83%) 5 (14%) 1 (2.8%) 6 (17%)
Traditional serrated adenoma 27 8 (30%) 14 (52%) 5 (19%) 19 (70%)
Tubular adenoma (TA) 393 154 (39%) 132 (34%) 107 (27%) 239 (61%)
Tubulovillous adenoma (TVA) 109 49 (45%) 27 (25%) 33 (30%) 60 (55%)
Villous adenoma (VA) 13 5 (38%) 5 (38%) 3 (23%) 8 (62%)
Total non-serrated adenomas (TA, TVA, and VA) 515 208 (40%) 164 (32%) 143 (28%) 307 (60%)
Adenoma with intramucosal carcinoma 33 8 (24%) 11 (33%) 14 (42%) 25 (76%)
Adenocarcinoma with serration 96 13 (14%) 18 (19%) 65 (68%) 83 (86%)
Adenocarcinoma without serration 111 18 (16%) 23 (21%) 70 (63%) 93 (84%)
Total adenocarcinomas 207 31 (15%) 41 (20%) 135 (65%) 176 (85%)BMC Cancer 2008, 8:33 http://www.biomedcentral.com/1471-2407/8/33
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mon in adenocarcinomas (85% = 176/207) than in non-
serrated adenomas (60% = 307/515, p < 0.0001) (Figure
4). There was a trend that COX-2 overexpression was pro-
gressively more common from non-serrated adenomas, to
adenomas with intramucosal carcinomas, and to adeno-
carcinomas.
Tumor location, gender, age at diagnosis, and COX-2 
overexpression in colorectal neoplasias
We also examined the relationship between tumor loca-
tion, histopathologic diagnosis and the frequency of
COX-2 overexpression (Table 2). There were no signifi-
cant differences in the frequencies of COX-2 overexpres-
sion between tumors in the proximal colon and those in
the distal colorectum in any histopathologic category.
Frequency of any (1+ or 2+) COX-2 overexpression in vari- ous colorectal neoplasias Figure 4
Frequency of any (1+ or 2+) COX-2 overexpression in vari-
ous colorectal neoplasias.
0% 25% 50% 75% 100%
Adenocarcinoma (N=207)
Adenoma with intramucosal carcinoma (N=33)
Non-serrated adenoma (TA, TVA, VA, N=515)
Villous adenoma (VA, N=13)
Tubulovillous adenoma (TVA, N=109)
Tubular adenoma (TA, N=393)
Serrated adenoma (N=27)
HP, SSA, MP (N=36)
SSA, MP (N=12)
Mixed polyp with SSA and adenoma (MP, N=5)
Sessile serrated polyp/adenoma (SSA, N=7)
Hyperplastic polyp (HP, N=24) P<0.0001
P=0.03
P<0.0001
Referent
P<0.0001
Frequency of strong (2+) COX-2 overexpression in various  colorectal neoplasias Figure 3
Frequency of strong (2+) COX-2 overexpression in various 
colorectal neoplasias.
0% 25% 50% 75% 100%
Adenocarcinoma (N=207)
Adenoma with intramucosal carcinoma (N=33)
Non-serrated adenoma (TA, TVA, VA, N=515)
Villous adenoma (VA, N=13)
Tubulovillous adenoma (TVA, N=109)
Tubular adenoma (TA, N=393)
Serrated adenoma (N=27)
HP, SSA, MP (N=36)
SSA, MP (N=12)
Mixed polyp with SSA and adenoma (MP, N=5)
Sessile serrated polyp/adenoma (SSA, N=7)
Hyperplastic polyp (HP, N=24)
P=0.0003
P=0.04
P=0.008
Referent
P<0.0001
Table 2: Frequency of COX-2 overexpression in colorectal tumors according to tumor location
Tumor type Total COX-2 negative COX-2 weak (1+) 
overexpression
COX-2 strong (2+) 
overexpression
COX-2 any (1+, 2+) 
overexpression
Proximal*
Hyperplastic polyp (HP) 5 5 (100%) 0 0 0
Sessile serrated polyp/adenoma (SSA) 2 2 (100%) 0 0 0
Mixed polyp with SSA and adenoma (MP) 1 1 (100%) 0 0 0
Traditional serrated adenoma 8 4 (50%) 3 (38%) 1 (13%) 4 (50%)
Tubular adenoma (TA) 120 53 (44%) 47 (39%) 20 (17%) 67 (56%)
Tubulovillous adenoma (TVA) 32 11 (34%) 9 (28%) 12 (38%) 21 (66%)
Villous adenoma (VA) 3 1 (33%) 1 (33%) 1 (33%) 2 (67%)
Adenoma with intramucosal carcinoma 7 3 (43%) 1 (14%) 3 (43%) 4 (57%)
Adenocarcinoma with serration 34 6 (18%) 7 (21%) 21 (62%) 28 (82%)
Adenocarcinoma without serration 31 8 (26%) 7 (23%) 16 (52%) 23 (74%)
Distal*
Hyperplastic polyp (HP) 17 14 (82%) 2 (12%) 1 (5.9%) 3 (28%)
Sessile serrated polyp/adenoma (SSA) 4 2 (50%) 2 (50%) 0 2 (50%)
Mixed polyp with SSA and adenoma (MP) 3 2 (67%) 1 (33%) 0 1 (33%)
Traditional serrated adenoma 19 4 (21%) 11 (58%) 4 (21%) 15 (79%)
Tubular adenoma (TA) 192 76 (40%) 57 (30%) 59 (31%) 116 (60%)
Tubulovillous adenoma (TVA) 65 35 (54%) 16 (25%) 14 (22%) 30 (46%)
Villous adenoma (VA) 9 4 (44%) 3 (33%) 2 (22%) 5 (56%)
Adenoma with intramucosal carcinoma 12 2 (17%) 5 (42%) 5 (42%) 10 (83%)
Adenocarcinoma with serration 34 3 (8.8%) 4 (12%) 27 (79%) 31 (91%)
Adenocarcinoma without serration 42 4 (9.5%) 9 (21%) 29 (69%) 38 (90%)
* Proximal tumors were located from cecum to transverse colon, and distal tumors were located from splenic flexure to rectum.BMC Cancer 2008, 8:33 http://www.biomedcentral.com/1471-2407/8/33
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Nonetheless, there was a trend towards more frequent
COX-2 overexpression in tumors in the distal colorectum
than those in the proximal colon (among hyperplastic
polyps, SSAs, mixed polyps, traditional serrated adeno-
mas and adenocarcinomas).
COX-2 overexpression was not correlated with gender or
age at diagnosis in any of the histopathologic categories
examined (data not shown).
Discussion
We conducted this study to examine COX-2 expression in
various serrated and non-serrated colorectal neoplasias.
We have demonstrated that, compared to non-serrated
adenomas, COX-2 overexpression is infrequent in hyper-
plastic polyps, sessile serrated polyps/adenomas (SSAs)
and mixed polyps with SSA and adenoma. Traditional ser-
rated adenoma and non-serrated adenoma show similar
frequencies of COX-2 overexpression. In addition, COX-2
overexpression appears to become frequent as tumors
progress to higher grade neoplasias, which is in agreement
with a previous study showing a positive correlation
between COX-2 expression and tumor grade in colorectal
adenomas [41].
SSAs have been named in a variety of ways in the literature
[19]. Torlakovic and Snover [42] found that the his-
topathologic features of polyps of "hyperplastic polypo-
sis" were different from those of small sporadic
hyperplastic polyps, and the term "sessile serrated ade-
noma" was coined to distinguish these distinct lesions
from the more pedunculated lesions of traditional ser-
rated adenomas [43]. Similar lesions have been reported
under different names, including "serrated adenoma,
superficial types" [44] and "serrated adenoma types 1 and
2" [45]. A recent review by Jass [23] used the term "sessile
serrated polyp" because "this lesion lacks the traditional
cytology of colorectal adenoma and in order to avoid con-
fusion with serrated adenoma, it is referred to in this
review as sessile serrated polyp". To reconcile this termi-
nology issue, we used the term "sessile serrated polyp/ade-
noma (SSA)".
A few previous studies have examined COX-2 expressions
in sporadic serrated adenomas as well as hyperplastic pol-
yps. Arao et al. [30] examined COX-2 expression in ser-
rated adenomas and hyperplastic polyps, and found that
71% of serrated adenomas showed moderate to intense
positivity, in contrast to 32% of hyperplastic polyps show-
ing weak to moderate positivity. Takeuchi et al. [29] exam-
ined COX-2 expression in serrated adenomas, tubular
adenomas and hyperplastic polyps, but not in SSAs. They
found that serrated adenomas of the cerebriform pattern
showed a similar COX-2 expression score as tubular ade-
nomas, and concluded that serrated adenoma of the cere-
briform pattern should be treated similarly as tubular
adenoma. There are other studies that have shown infre-
quent COX-2 overexpression in hyperplastic polyps
[2,31]. However, to our knowledge, no study to date has
compared COX-2 expression levels between SSAs, tradi-
tional serrated adenomas, non-serrated adenomas and
adenocarcinomas.
The serrated pathway of colorectal carcinogenesis has
been linked to widespread promoter methylation referred
to as the CpG island methylator phenotype (CIMP)
[23,46]. CIMP-high colorectal cancers are inversely corre-
lated with COX-2 overexpression independent of MSI sta-
tus [27]. Together with our current data on the inverse
association between COX-2 and the serrated polyps, these
observations support the proposed link between the ser-
rated pathway and CIMP-high in colorectal cancer devel-
opment.
Our data may have significant clinical implications
because of emerging importance of COX-2 as a promising
chemopreventive target [10,18]. Regular aspirin use has
been shown to decrease risks of colorectal cancer as well
as adenoma [8,9]. We have recently shown that regular
aspirin use decreases a risk of COX-2-overexpressing
colorectal cancer, but not a risk of COX-2-negative color-
ectal cancer [10]. In light of our findings, aspirin,
celecoxib, and other non-steroidal anti-inflammatory
drugs (NSAIDs) may be less frequently effective against
serrated polyps than non-serrated adenomas. However,
since COX-2 overexpression also appears to be dependent
on tumor progression, it is possible that COX-2 inhibition
may still be effective for the prevention of tumor progres-
sion in a subset of any types of precursor lesions.
Conclusion
In conclusion, hyperplastic polyp, sessile serrated polyp/
adenoma (SSA) and mixed polyp with SSA and adenoma
infrequently overexpress COX-2, when compared to non-
serrated adenomas and serrated adenomas. COX-2 over-
expression appears to be more frequent as tumors
progress. Our observations suggest that COX-2 may play a
less significant role in the serrated pathway of tumorigen-
esis, especially in early stage of polyp formation; however,
COX-2 may still play a role in later stage of the serrated
pathway.
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